Provided by Tiger Trade Technology Pte. Ltd.

Soleno Therapeutics

30.05
-1.8100-5.68%
Post-market: 32.902.85+9.48%18:43 EDT
Volume:1.76M
Turnover:52.96M
Market Cap:1.55B
PE:77.05
High:32.37
Open:31.73
Low:29.43
Close:31.86
52wk High:90.32
52wk Low:29.43
Shares:51.62M
Float Shares:44.87M
Volume Ratio:1.11
T/O Rate:3.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3900
EPS(LYR):0.3900
ROE:6.01%
ROA:2.09%
PB:3.45
PE(LYR):77.05

Loading ...

Stifel Nicolaus Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

TIPRANKS
·
Nov 05, 2025

Soleno Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Nov 05, 2025

Stock Track | Soleno Therapeutics Plummets 26.69% Despite Strong Q3 Earnings, Puzzling Investors

Stock Track
·
Nov 05, 2025

Stock Track | Soleno Therapeutics Plunges 21% Pre-Market Despite Strong Q3 Earnings Beat

Stock Track
·
Nov 05, 2025

Stock Track | Soleno Therapeutics Plummets 21.39% in Pre-market Despite Strong Q3 Earnings, Puzzling Investors

Stock Track
·
Nov 05, 2025

Soleno Therapeutics: Strong Sales Growth and Profitability Drive Buy Rating

TIPRANKS
·
Nov 05, 2025

Stock Track | Soleno Therapeutics Plunges 20% Despite Strong Q3 Earnings, Beating Expectations

Stock Track
·
Nov 05, 2025

Stock Track | Soleno Therapeutics Plunges 15.43% After Hours Despite Positive Q3 Earnings

Stock Track
·
Nov 05, 2025

Soleno Therapeutics posts Q3 profit on strong VYKAT XR sales

Reuters
·
Nov 05, 2025

Soleno Therapeutics Q3 EPS $0.47 Beats $0.06 Estimate, Sales $66.000M Beat $48.095M Estimate

Benzinga
·
Nov 05, 2025

BRIEF-Soleno Therapeutics Q3 EPS USD 0.47

Reuters
·
Nov 05, 2025

Soleno Therapeutics Q3 Operating Expenses USD 43.913 Million

THOMSON REUTERS
·
Nov 05, 2025

Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of Vykat(Tm) Xr

THOMSON REUTERS
·
Nov 05, 2025

Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR

GlobeNewswire
·
Nov 05, 2025

Soleno Therapeutics options imply 15.9% move in share price post-earnings

TIPRANKS
·
Nov 05, 2025

Did New Legal Scrutiny Around VYKAT XR Just Shift Soleno Therapeutics' (SLNO) Investment Narrative?

Simply Wall St.
·
Nov 02, 2025

Soleno Therapeutics to Participate in Upcoming November Conferences

GlobeNewswire
·
Oct 28, 2025

Cassava Sciences Appoints Dawn C. Bir to Board of Directors

Reuters
·
Oct 22, 2025

Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET

GlobeNewswire
·
Oct 21, 2025

Does Soleno Therapeutics’ (SLNO) Board Expansion Hint at a Shift in Governance Amid VYKAT XR Scrutiny?

Simply Wall St.
·
Oct 18, 2025